amphotora/E+ via Getty Images Introduction On May 29, I wrote an article titled "Looking For Both Income And Growth? 4%-Yielding AbbVie Has You Covered." Since then, shares of the Abbott Laboratories (ABT) spin-off have returned roughly 30%, beating the S&P 500 by 23 points. Since becoming independent in April 2012, AbbVie Inc. (NYSE:ABBV) has returned 810%, beating both the S&P 500 and the healthcare ETF (XLV). Data by YCharts Although I'm obviously happy, my thesis has turned out to be correct, it's impor ...